ppgl-pregnancy-surgical-timing

name	ppgl-pregnancy-surgical-timing
description	Determines optimal timing for surgical tumor removal in pregnant PPGL patients to balance maternal and fetal risks. Triggered by PPGL diagnosed in pregnant patient, assessing surgical feasibility during pregnancy, or planning intervention for PPGL in gestation.

Pregnancy-Specific PPGL Surgical Timing

STEP 1 — Gather Information

Confirm PPGL diagnosis via fractionated metanephrines (urine or plasma) and safe imaging (ultrasound or MRI). Document gestational age, tumor size/location, maternal hypertension/symptoms, and fetal status.

STEP 2 — Rule In / Rule Out

Assess if tumor resection is feasible before delivery: gestational age <24 weeks and tumor resectable. If yes, rule in for surgery; if gestational age ≥24 weeks or tumor unresectable, rule out immediate resection.

STEP 3 — Classify or Stratify

If feasible (<24 weeks), classify as candidate for second-trimester resection up to 24 weeks gestation. If not feasible (≥24 weeks), stratify to medical management until fetal viability.

STEP 4 — Decide

For feasible cases, proceed with laparoscopic tumor resection after adequate α-blockade (e.g., doxazosin) in the second trimester up to 24 weeks. For infeasible cases, initiate medical management (α-blockers ± calcium antagonists) and plan delivery/tumor removal after fetal viability.

Clinical Guardrails / Mimics / Pitfalls

Avoid CT and 123I-MIBG scintigraphy unless radiation benefits outweigh risks; do not use metyrosine due to limited safety data in pregnancy; avoid ARBs, ACE-Is, and direct renin inhibitors; never administer β-blockers before α-blockade; monitor for hypertensive crisis; consider cesarean section if tumor not resected pre-delivery.

Concrete Clinical Example

A 28‑year‑old at 18 weeks gestation presents with hypertension and palpitations; elevated urinary fractionated metanephrines; MRI shows 3 cm left adrenal tumor. After α‑blockade with doxazosin, laparoscopic adrenalectomy performed at 20 weeks; pregnancy continues uneventfully to term.

Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165